ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.869,65
1,23%
S&P 500
5.998,74
0,00%
Dow Jones
44.910,65
0,00%
Euro vs US Dollar
1,05135
-0,28%
Bitcoin
95.549,65
-1,76%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sigilon Therapeutics Inc (SGTX)

  7. Sigilon Therapeutics Inc (SGTX) News

SGTX

Sigilon Therapeutics (SGTX)

Sigilon Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SGTX
DatumZeitQuelleÜberschriftSymbolFirma
21/08/202314h22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGTXSigilon Therapeutics Inc
16/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGTXSigilon Therapeutics Inc
14/08/202313h25PR Newswire (US)Lilly Completes Acquisition of Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
10/08/202314h31Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
07/08/202314h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGTXSigilon Therapeutics Inc
01/08/202322h06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
27/07/202322h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
25/07/202301h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
18/07/202322h03Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
13/07/202314h18Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202313h35Dow Jones NewsEli Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202313h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202313h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202312h57Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202312h45PR Newswire (US)Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202322h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGTX

Kürzlich von Ihnen besucht

BIT
TUR
ETF
TSXV
KANA
Kanadario Gold
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€